Literature DB >> 23486482

Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells.

Laura M Hix1, John Karavitis, Mohammad W Khan, Yihui H Shi, Khashayarsha Khazaie, Ming Zhang.   

Abstract

Previous studies had implicated the IFN-γ transcription factor signal transducer and activator of transcription 1 (STAT1) as a tumor suppressor. However, accumulating evidence has correlated increased STAT1 activation with increased tumor progression in multiple types of cancer, including breast cancer. Indeed, we present evidence that tumor up-regulation of STAT1 activity in human and mouse mammary tumors correlates with increasing disease progression to invasive carcinoma. A microarray analysis comparing low aggressive TM40D and highly aggressive TM40D-MB mouse mammary carcinoma cells revealed significantly higher STAT1 activity in the TM40D-MB cells. Ectopic overexpression of constitutively active STAT1 in TM40D cells promoted mobilization of myeloid-derived suppressor cells (MDSCs) and inhibition of antitumor T cells, resulting in aggressive tumor growth in tumor-transplanted, immunocompetent mice. Conversely, gene knockdown of STAT1 in the metastatic TM40D-MB cells reversed these events and attenuated tumor progression. Importantly, we demonstrate that in human breast cancer, the presence of tumor STAT1 activity and tumor-recruited CD33(+) myeloid cells correlates with increasing disease progression from ductal carcinoma in situ to invasive carcinoma. We conclude that STAT1 activity in breast cancer cells is responsible for shaping an immunosuppressive tumor microenvironment, and inhibiting STAT1 activity is a promising immune therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23486482      PMCID: PMC3636858          DOI: 10.1074/jbc.M112.441402

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

Authors:  S Demaria; M D Volm; R L Shapiro; H T Yee; R Oratz; S C Formenti; F Muggia; W F Symmans
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.

Authors:  C M Perou; S S Jeffrey; M van de Rijn; C A Rees; M B Eisen; D T Ross; A Pergamenschikov; C F Williams; S X Zhu; J C Lee; D Lashkari; D Shalon; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 4.  Tumor necrosis factor, cancer and anticancer therapy.

Authors:  Simone Mocellin; Carlo Riccardo Rossi; Pierluigi Pilati; Donato Nitti
Journal:  Cytokine Growth Factor Rev       Date:  2004-12-19       Impact factor: 7.638

5.  Mechanism of cyclooxygenase-2 upregulation in late preconditioning.

Authors:  Yu-Ting Xuan; Yiru Guo; Yanqing Zhu; Hui Han; Robert Langenbach; Buddhadeb Dawn; Roberto Bolli
Journal:  J Mol Cell Cardiol       Date:  2003-05       Impact factor: 5.000

6.  T cell recruitment from the thymus to the spleen in tumor-bearing mice. I. Analysis of recruited cells by surface markers.

Authors:  K Tanaka; Y Koga; K Taniguchi; K Kamikaseda; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.

Authors:  Cecilia Melani; Claudia Chiodoni; Guido Forni; Mario P Colombo
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

9.  STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells.

Authors:  Nikolai N Khodarev; Michael Beckett; Edwardine Labay; Thomas Darga; Bernard Roizman; Ralph R Weichselbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-30       Impact factor: 11.205

Review 10.  Modeling human breast cancer metastasis in mice: maspin as a paradigm.

Authors:  H Y Shi; W Zhang; R Liang; F Kittrell; N S Templeton; D Medina; M Zhang
Journal:  Histol Histopathol       Date:  2003-01       Impact factor: 2.303

View more
  61 in total

1.  Cancer progression modeling using static sample data.

Authors:  Yijun Sun; Jin Yao; Norma J Nowak; Steve Goodison
Journal:  Genome Biol       Date:  2014-08-26       Impact factor: 13.583

2.  Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer.

Authors:  Maurizio Callari; Valeria Musella; Eleonora Di Buduo; Marialuisa Sensi; Patrizia Miodini; Matteo Dugo; Rosaria Orlandi; Roberto Agresti; Biagio Paolini; Maria Luisa Carcangiu; Vera Cappelletti; Maria Grazia Daidone
Journal:  Mol Oncol       Date:  2014-05-04       Impact factor: 6.603

Review 3.  Energy metabolic pathways control the fate and function of myeloid immune cells.

Authors:  Amir A Al-Khami; Paulo C Rodriguez; Augusto C Ochoa
Journal:  J Leukoc Biol       Date:  2017-05-17       Impact factor: 4.962

4.  The differential interferon responses of two strains of Stat1-deficient mice do not alter susceptibility to HSV-1 and VSV in vivo.

Authors:  Sarah Katzenell; Yufei Chen; Zachary M Parker; David A Leib
Journal:  Virology       Date:  2014-01-14       Impact factor: 3.616

5.  CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

Authors:  Abdul S Qadir; Paolo Ceppi; Sonia Brockway; Calvin Law; Liang Mu; Nikolai N Khodarev; Jung Kim; Jonathan C Zhao; William Putzbach; Andrea E Murmann; Zhuo Chen; Wenjing Chen; Xia Liu; Arthur R Salomon; Huiping Liu; Ralph R Weichselbaum; Jindan Yu; Marcus E Peter
Journal:  Cell Rep       Date:  2017-03-07       Impact factor: 9.423

Review 6.  IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression.

Authors:  Hussein F Aqbi; Matthew Wallace; Samay Sappal; Kyle K Payne; Masoud H Manjili
Journal:  J Leukoc Biol       Date:  2018-02-22       Impact factor: 4.962

7.  The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer.

Authors:  Mohammad W Khan; Abdulrahman Saadalla; Ahmed H Ewida; Khalid Al-Katranji; Ghadier Al-Saoudi; Zachary T Giaccone; Fotini Gounari; Ming Zhang; David A Frank; Khashayarsha Khazaie
Journal:  Cancer Immunol Immunother       Date:  2017-09-05       Impact factor: 6.968

8.  Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.

Authors:  Jinah Park; Junil Kim; Bora Park; Kyung-Min Yang; Eun Jin Sun; Cristina E Tognon; Poul H Sorensen; Seong-Jin Kim
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

9.  RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation.

Authors:  Ryan C Widau; Akash D Parekh; Mark C Ranck; Daniel W Golden; Kiran A Kumar; Ravi F Sood; Sean P Pitroda; Zhengkai Liao; Xiaona Huang; Thomas E Darga; David Xu; Lei Huang; Jorge Andrade; Bernard Roizman; Ralph R Weichselbaum; Nikolai N Khodarev
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

Review 10.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Authors:  Katherine H Parker; Daniel W Beury; Suzanne Ostrand-Rosenberg
Journal:  Adv Cancer Res       Date:  2015-05-12       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.